 |
(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt |
|---|---|
| Trade Name | |
| Orphan Indication | Idiopathic pulmonary fibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2011-04-15 00:00:00 |
| Sponsor | Bristol-Myers Squibb Company;P. O. Box 4000;Princeton, New Jersey, 08543 |
